Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSmiths Group Regulatory News (SMIN)

Share Price Information for Smiths Group (SMIN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,681.00
Bid: 1,686.00
Ask: 1,687.00
Change: -27.00 (-1.58%)
Spread: 1.00 (0.059%)
Open: 1,708.00
High: 1,709.00
Low: 1,679.00
Prev. Close: 1,708.00
SMIN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Management Statement

23 May 2014 07:00

RNS Number : 9009H
Smiths Group PLC
23 May 2014
 

 

News Release

London, 23 May 2014

For immediate release

 

 

SMITHS GROUP PLC INTERIM MANAGEMENT STATEMENT

 

In the nine months to 3 May 2014, underlying revenue at Smiths Group was slightly weaker than the prior period as growth in John Crane and Flex-Tek was more than offset by weakness in Detection, Medical and Interconnect. The full year outlook for headline operating profit is in line with expectations for all businesses except Smiths Detection where profitability is now expected to be £25m lower due to a combination of working capital adjustments, reduced volumes and contract mix on lower margin contracts and additional programme delivery costs. The headwind from foreign exchange translation for the Group overall is in line with previous guidance and, at current rates, is expected to be an adverse impact of c. 5% on full year earnings.

 

In the first nine months, John Crane delivered revenue growth at constant currencies supported by a growing order book, which continues to be at record levels. Demand remains strong from mid- and downstream energy services customers particularly in the USA, Middle East, Asia and Brazil. The upstream energy services business continues to face some headwinds. Underlying headline operating profit also grew on the back of productivity gains and favourable mix. As a result, John Crane is expected to grow in line with the outlook given at the half year results in March.

 

Smiths Medical saw a return to underlying growth in third quarter revenues as the impact of US distributor destocking subsided, although year to date underlying revenues still remain below the prior period. Headline operating profit in the first nine months has been constrained by operational gearing effects related to the lower volumes, continued tough trading in developed markets and the introduction of the US medical device tax. The outlook for the full year is still expected to be below the prior year, as previously guided, although we continue to anticipate a stronger trading performance in the second half than the first.

 

Smiths Detection faced further challenging trading conditions during the third quarter. Underlying revenue declined in the nine months primarily reflecting weaker demand from cargo screening and transportation, albeit against a strong comparator period. During the quarter, following an assessment of all major contracts and programmes, we concluded a review of working capital requirements. This review, combined with the adoption of new divisional policies, will result in a full year charge of around £12m for the associated adjustments to inventory and receivables. Full year profitability will also be impacted by c. £9m from lower volumes and adverse mix from lower margin contracts and by around £4m of additional programme delivery costs from certain long-running large contracts. Although our drive for operational improvements and manufacturing efficiencies continues, full year headline operating profit will be adversely affected by these additional costs. A new divisional president was appointed this month and his immediate priority is to focus on addressing the shortcomings in programme delivery and on improving revenue and margin performance in line with the operating ranges already set out. These initiatives to address low margin programmes and other ongoing productivity initiatives are likely to take another 18 months.

 

Smiths Interconnect saw an improving trend during the third quarter, with greater profitability and a slowing rate of underlying revenue decline. Year to date revenue and headline operating profit are below the prior year at constant currencies. Underlying revenue growth from commercial markets such as telecommunications in Microwave, semiconductor test in Connectors and data centres in Power has been offset by weaker demand from defence customers across all business units. Looking to the full year, the improving revenue trend is expected to continue, with strengthening margins benefiting from productivity gains.

 

Flex-Tek has made good progress growing underlying revenue through a strong performance in US residential construction and in specialty heating elements. Headline operating profit and margins improved strongly as a result of the higher volumes and efficiencies. The outlook for the full year remains positive driven by the aerospace order book and US housing.

 

At 3 May, net debt was £895m, slightly reduced from the £901m at 31 January 2014.

 

ENDS

This press release contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group. By their nature, these statements involve uncertainty since future events and circumstances can cause results and developments to differ materially from those anticipated. The forward-looking statements reflect knowledge and information available at the date of preparation of the press release and the Company undertakes no obligation to update these forward-looking statements. Nothing in this press release should be construed as a profit forecast.

 

 

Investor Relations

Peter Durman: +44 (0)20 7808 5535

 

Media Relations

Colin McSeveny: +44 (0)20 7808 5534

Anthony Cardew - Cardew Group: +44 (0)20 7930 0777

 

Smiths Group

Smiths is a global technology company listed on the London Stock Exchange (SMIN) and operates a sponsored level one ADR programme (SMGZY). A world leader in the practical application of advanced technologies, Smiths Group delivers products and services for the threat & contraband detection, medical devices, energy and communications markets worldwide. Our products and services make the world safer, healthier and more productive. Smiths Group employs around 23,000 people in over 50 countries. For more information visit www.smiths.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSLIFFEESIVFIS
Date   Source Headline
14th Jun 20247:00 amRNSTransaction in Own Shares
13th Jun 20247:00 amRNSTransaction in Own Shares
12th Jun 20247:00 amRNSTransaction in Own Shares
11th Jun 20247:00 amRNSTransaction in Own Shares
10th Jun 20247:00 amRNSTransaction in Own Shares
7th Jun 20247:00 amRNSTransaction in Own Shares
6th Jun 20247:00 amRNSTransaction in Own Shares
5th Jun 20247:00 amRNSTransaction in Own Shares
4th Jun 20247:00 amRNSTransaction in Own Shares
3rd Jun 20243:35 pmRNSTotal Voting Rights
3rd Jun 202410:00 amRNSDirectorate Change
3rd Jun 20247:00 amRNSTransaction in Own Shares
31st May 20247:00 amRNSTransaction in Own Shares
21st May 20247:00 amRNSSmiths Group 3rd Quarter Results
16th May 20249:30 amRNSDirector/PDMR Shareholding
8th May 20247:00 amRNSTransaction in Own Shares
7th May 20247:00 amRNSTransaction in Own Shares
3rd May 20247:00 amRNSTransaction in Own Shares
2nd May 20247:00 amRNSTransaction in Own Shares
1st May 20244:45 pmRNSDirector/PDMR Shareholding
1st May 20243:30 pmRNSTotal Voting Rights
1st May 202410:00 amRNSBlock listing Interim Review
1st May 20247:00 amRNSTransaction in Own Shares
30th Apr 20247:00 amRNSTransaction in Own Shares
29th Apr 20247:00 amRNSTransaction in Own Shares
26th Apr 20247:00 amRNSTransaction in Own Shares
25th Apr 20247:00 amRNSTransaction in Own Shares
24th Apr 20247:00 amRNSTransaction in Own Shares
23rd Apr 20247:00 amRNSTransaction in Own Shares
22nd Apr 20247:00 amRNSTransaction in Own Shares
19th Apr 20247:00 amRNSTransaction in Own Shares
18th Apr 20247:00 amRNSTransaction in Own Shares
17th Apr 20247:00 amRNSTransaction in Own Shares
16th Apr 20247:00 amRNSTransaction in Own Shares
15th Apr 20247:00 amRNSTransaction in Own Shares
12th Apr 20247:00 amRNSTransaction in Own Shares
11th Apr 20247:00 amRNSTransaction in Own Shares
10th Apr 20247:00 amRNSTransaction in Own Shares
9th Apr 20249:00 amRNSDirector/PDMR Shareholding
9th Apr 20247:00 amRNSTransaction in Own Shares
8th Apr 20247:00 amRNSTransaction in Own Shares
5th Apr 20247:00 amRNSTransaction in Own Shares
3rd Apr 20247:00 amRNSTransaction in Own Shares
2nd Apr 20244:30 pmRNSTotal Voting Rights
27th Mar 20247:00 amRNSTransaction in Own Shares
26th Mar 20247:15 amRNSShare buyback programme
26th Mar 20247:01 amRNSSmiths Group half year results
26th Mar 20247:00 amRNSDirectorate Change
1st Mar 20247:00 amRNSSmiths sells 830,000 shares in ICU Medical Inc
29th Feb 20249:00 amRNSDirectors' Change in Responsibilities

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.